IDEXX Laboratories (IDXX) Stock Forecast & Price Target

$495.42

-9.80 (-1.94%)

(As of 10/1/2024 ET)

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
2

Buy
7

Based on 9 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, and 7 have given a buy rating for IDXX.

Consensus Price Target

$582.25
17.53% Upside

According to the 9 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $582.25. The highest price target for IDXX is $650.00, while the lowest price target for IDXX is $510.00. The average price target represents a forecasted upside of 17.53% from the current price of $495.42.

Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

IDXX Analyst Ratings Over Time

Type	Current Forecast 10/3/23 to 10/2/24	1 Month Ago 9/3/23 to 9/2/24	3 Months Ago 7/5/23 to 7/4/24	1 Year Ago 10/3/22 to 10/3/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	4 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$582.25	$582.25	$586.63	$571.67
Forecasted Upside	17.53% Upside	20.97% Upside	22.86% Upside	34.44% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEXX Laboratories Stock vs. The Competition

Type	IDEXX Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	17.53% Upside	807.92% Upside	6.86% Upside
News Sentiment Rating	Positive News See Recent IDXX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/14/2024	Piper Sandler 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$600.00 ➝ $520.00	+9.78%
7/25/2024	BTIG Research 2 of 5 stars	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$580.00	+23.05%
6/24/2024	Stifel Nicolaus 4 of 5 stars		Lower Target	Hold ➝ Hold	$520.00 ➝ $510.00	+2.88%
5/14/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$620.00 ➝ $596.00	+15.88%
5/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$655.00 ➝ $570.00	+20.27%
4/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
Get the Latest News and Ratings for IDXX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.
2/6/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$600.00 ➝ $630.00	+11.83%
1/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$500.00 ➝ $650.00	+25.68%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$602.00	+15.42%
8/2/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$610.00	+14.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:15 AM ET.

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 9, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

Strong Consensus Rating: IDEXX Laboratories currently has a consensus rating of "Moderate Buy," indicating positive sentiment from analysts.
Consistent Revenue Growth: IDEXX Laboratories reported a revenue increase of 6.4% in the latest quarter, showcasing a healthy growth trajectory.
Healthy Return on Equity: With a return on equity of 63.66%, IDEXX Laboratories demonstrates efficient utilization of shareholder equity.
Market Cap and Stability: IDEXX Laboratories has a market cap of $40.65 billion, reflecting its size and stability in the market.
Attractive Stock Price: IDEXX Laboratories stock is currently trading at $492.26, showing potential for value appreciation.

IDEXX Laboratories
Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

Earnings Miss: IDEXX Laboratories reported earnings per share of $2.44 for the latest quarter, falling short of analysts' consensus estimates.
Decrease in Stock Price: IDEXX Laboratories stock traded down 0.6% recently, indicating short-term downward pressure.
Insider Selling: Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock, potentially signaling lack of confidence from insiders.
Debt-to-Equity Ratio: IDEXX Laboratories has a debt-to-equity ratio of 0.40, which may raise concerns about its financial leverage.
Lower Analyst Estimates: Analysts forecast IDEXX Laboratories to post 11 EPS for the current year, potentially lower than previous expectations.

IDXX Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $582.25, with a high forecast of $650.00 and a low forecast of $510.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.
: According to analysts, IDEXX Laboratories's stock has a predicted upside of 17.53% based on their 12-month stock forecasts.
: IDEXX Laboratories has been rated by research analysts at BTIG Research, and Piper Sandler in the past 90 days.
: Analysts like IDEXX Laboratories less than other "medical" companies. The consensus rating score for IDEXX Laboratories is 2.78 while the average consensus rating score for "medical" companies is 2.78. Learn more on how IDXX compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The world’s smartest man is in their crosshairs (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

This page (NASDAQ:IDXX) was last updated on 10/2/2024 by MarketBeat.com Staff

From Our Partners